We have been investigating therapeutic angiogenesis with basic fibroblast growth factor (bFGF) using gelatin hydrogel as a drug delivery system (DDS) in animal models. After we assessed the effectiveness of this new therapeutic technology in animal limb ischemia models and myocardial ischemia models, we recently completed human clinical studies in those settings. This novel therapy clearly has a potential to enhance neovascularization in ischemic lower limb and myocardium, and improves clinical symptoms. In this review, we describe the outcomes of our animal experiments and human clinical studies, and discuss the future perspectives.
There are many drug delivery system technologies applied to endovascular intervention. For vascular lesion, drug-eluting stents are widely used in percutaneous coronary intervention, and drug-eluting balloons are gradually used both in coronary artery disease and peripheral artery disease. For tumor lesion, drug delivery system technologies are widely used in trans-catheter arterial chemoembolization for the treatment of hepatocellular carcinoma. In this article, we will review these technologies and mention to our approach to apply drug delivery system technologies to the endovascular treatment of cerebral aneurysms.
Recently, regenerative medicine with autologous cells and tissues has been carried out for tissue regeneration. Basic research and clinical application based on tissue engineering have also been reported in joint cartilage regeneration. The physiological connection between the cartilages newly regenerated and natural ones is not always sufficient. Currently, to tackle the problem, the clinical application of DDS-based cartilage regeneration therapy has been tried. This paper introduces the research results of bone regeneration and articular cartilage regeneration in the veterinary medical field.
Conventional vaccination is performed mainly by injection, which has several inherent problems: pain, the need for trained personnel, associated needle-related diseases or injuries, and storage or transport issues. In some areas, vaccine coverage against infection is low due to failure in follow-up as well as a lack of trained medical personnel and facilities. Thus, the development of needle-free, easy-to-use, and low-invasive vaccination methods is an urgent task. With its advantages that overcome the inherent problems of vaccination by injection, transcutaneous immunization is now attracting attention as an alternative vaccination route. Herein, we provide an outline of recent trends in the development of transcutaneous vaccine formulations utilizing the microneedle technology.
Endogenous stem cells are promising sources for low-cost and minimally invasive regenerative medicine. Recent studies suggest that drug delivery system technologies are useful to promote proliferation, differentiation and migration of various types of cells during regeneration processes. In this paper, we introduce recent progress in regenerative medicine using the drug delivery system.
Considering “drug” as “a substance to show a certain activity”, drug delivery system (DDS) can be applied for various fields, such as living environment, health care, and bio-medical research other than medicine and pharmaceutical science. The objective of bio-medical research is to elucidate the complicated and detailed mechanism underlying the life phenomena and therapeutic effect. The bio-medical research will be further developed by making use of DDS technologies for key substances which control and detect the cellular biological functions and dynamics. This review overviews DDS technologies which can apply to the biomedical research in terms of the artificial manipulation of substances. In addition, DDS technologies for new technology fields which are expected to further develop the bio-medical research in future, are introduced.
[Serial] Front line of DDS development in pharmaceutical industries
CLENAFIN® topical solution 10% is the country’s first topical treatment for onychomycosis, launched in Japan in September 2014. CLENAFIN® contains efinaconazole, novel triazole antifungal drug as its active ingredient. Efinaconazole does not bind well with keratin, the main component of nails, meaning that this drug has superior nail penetrating properties. CLENAFIN® has proven effective in treating onychomycosis through once-daily application to the infected nails. CLENAFIN® comes packaged in a bottle with a connected brush, making it easy to apply the drug across the surface of nails.
[Serial] Reviews on useful reagents for DDS research and development
April 03, 2017 There had been a system trouble from April 1, 2017, 13:24 to April 2, 2017, 16:07(JST) (April 1, 2017, 04:24 to April 2, 2017, 07:07(UTC)) .The service has been back to normal.We apologize for any inconvenience this may cause you.
May 18, 2016 We have released “J-STAGE BETA site”.
May 01, 2015 Please note the "spoofing mail" that pretends to be J-STAGE.